Lung Cancer Trial, Recruiting (NCT06386107)

Lung Cancer Trial, Recruiting NCT06386107 Sponsor: Centre Hospitalier Universitaire de Saint Etienne Condition: Lung Cancer

Printed from Voxsanity (voxsanity.com.au) — NCT06386107 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Lung Cancer

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You have an active cancer diagnosis, as defined by current French medical guidelines
You have been recently diagnosed with a serious blood clot — either a deep vein thrombosis (a clot in a large vein, usually in the leg) and/or a pulmonary embolism (a clot in the lungs), confirmed by a scan or ultrasound
You are able to safely receive full-dose blood-thinning medication at the time of joining the trial

Who may not be able to join:

You are already taking part in another clinical trial that involves a treatment (whether the treatment is known or unknown to you) and you are in the active treatment group
You are already taking full-dose blood-thinning medication for a heart valve condition, an irregular heart rhythm, or a previous blood clot
Your cancer is a blood cancer (such as leukaemia or lymphoma)
You have a medical reason why you cannot safely take blood-thinning medication
You have already been switched over to a type of blood-thinning tablet called a DOAC (a newer oral anticoagulant pill)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 30 June 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06386107

Sponsor: Centre Hospitalier Universitaire de Saint Etienne

Phase: Not Applicable

Status: Recruiting

Condition: Lung Cancer

More information: https://clinicaltrials.gov/study/NCT06386107

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You have an active cancer diagnosis, as defined by current French medical guidelines
You have been recently diagnosed with a serious blood clot — either a deep vein thrombosis (a clot in a large vein, usually in the leg) and/or a pulmonary embolism (a clot in the lungs), confirmed by a scan or ultrasound
You are able to safely receive full-dose blood-thinning medication at the time of joining the trial

Who may not be able to join:

You are already taking part in another clinical trial that involves a treatment (whether the treatment is known or unknown to you) and you are in the active treatment group
You are already taking full-dose blood-thinning medication for a heart valve condition, an irregular heart rhythm, or a previous blood clot
Your cancer is a blood cancer (such as leukaemia or lymphoma)
You have a medical reason why you cannot safely take blood-thinning medication
You have already been switched over to a type of blood-thinning tablet called a DOAC (a newer oral anticoagulant pill)

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 30 June 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Centre Hospitalier Universitaire de Saint Etienne

Registry

ClinicalTrials.gov

Start date

2 September 2025

Est. completion

1 July 2027

Where this trial is recruiting

🇫🇷 France

Primary endpoints

The measurement of the area under the curve ( endogenious thrombin potential) nMxmin; the measurement of the lag time unit = seconds; the measurement of the peak height unit = nm; the measurement of the time to peak unit = seconds

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov